IDT launches new CRISPR analysis system

IDT, genomics solutions provider, has launched a new system to provide an end-to-end solution for characterising and quantifying the full array of on and off-target genome editing events in CRISPR research projects, and other genome editing projects.

The system uses IDT rhAmpSeq technology, which is designed to enable accurate amplicon sequencing on Illumina next generation sequencing (NGS) platforms. The rhAmpSeq CRISPR Analysis System consists of design and synthesis of a custom rhAmpSeq CRISPR Panel, an efficient library kit, and access to data analysis through a user-friendly interface. This system enables sample-to-sequencer-to-results in less than a week.

Trey Martin, IDT President, said: “As genome editing becomes more widespread, it is crucial to validate the editing and identify off-target effects. The rhAmpSeq CRISPR Analysis System addresses and uniquely enables this important researcher need.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free